OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares

Rhea-AI Filing Summary

OKYO Pharma Limited reported that Chief Executive Officer Robert J. Dempsey purchased 15,000 ordinary shares of the company on Nasdaq at $1.54 per share on July 23, 2026.

OKYO is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases and plans a global Phase 3 pivotal trial of urcosimod in the second half of this year, enrolling approximately 111 patients on a single-dose regimen.

Key Figures

CEO share purchase: 15,000 ordinary shares Purchase price: $1.54 per share Planned Phase 3 trial size: approximately 111 patients +1 more

4 metrics

CEO share purchase 15,000 ordinary shares Purchased on Nasdaq by CEO Robert J. Dempsey

Purchase price $1.54 per share Price paid for ordinary shares in the CEO’s purchase

Planned Phase 3 trial size approximately 111 patients Planned enrollment for global Phase 3 urcosimod NCP trial

Announcement date July 23, 2026 Date of news announcing the CEO’s share purchase

Key Terms

neuropathic corneal pain, anterior segment eye diseases, Phase 3 pivotal clinical trial, single-dose regimen, +1 more

5 terms

neuropathic corneal pain medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

anterior segment eye diseases medical

"therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases"

Diseases of the anterior segment of the eye are medical conditions that affect the front part of the eye—including the cornea, iris, lens, and the front chamber—similar to damage or fogging on a car’s windshield that interferes with vision. They matter to investors because this category drives demand for drugs, surgical devices, diagnostic tools, and clinical trials; prevalence, regulatory approvals, and reimbursement decisions can directly affect companies’ revenues and valuations.

Phase 3 pivotal clinical trial medical

"plans to initiate a global Phase 3 pivotal clinical trial in the second half"

A phase 3 pivotal clinical trial is the late-stage, large-scale human study designed to confirm a medical treatment’s safety and effectiveness and provide the main evidence regulators use to decide on approval. For investors it’s a make-or-break test: a successful result is like a final dress rehearsal that clears the way for product launch and future sales, while failure can halt development and erase expected value.

single-dose regimen medical

"to evaluate a single-dose regimen of urcosimod for the treatment of NCP"

A single-dose regimen is a treatment plan in which a medication or vaccine is administered just once to produce the intended protective or therapeutic effect, rather than through multiple injections or pills over days or weeks. It matters to investors because single-dose products can simplify distribution, lower treatment costs, improve patient adherence, and change market demand and regulatory review timelines—much like a one-time purchase versus an ongoing subscription.

urcosimod medical

"evaluate a single-dose regimen of urcosimod for the treatment of NCP"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/23/2026 - 07:00 AM Accepted by SEC EDGAR 07/23/2026 - 07:00 AM Learn about SEC filing dates

FAQ

What insider share purchase did OKYO (OKYO) disclose?

OKYO Pharma disclosed that CEO Robert J. Dempsey bought 15,000 ordinary shares on Nasdaq at $1.54 per share on July 23, 2026. The purchase involves the company’s Nasdaq-listed ordinary shares and was highlighted in a company news announcement.

At what price were the OKYO (OKYO) shares bought by the CEO?

The CEO purchased OKYO Pharma shares at $1.54 per share on Nasdaq. The transaction covered 15,000 ordinary shares and was carried out on July 23, 2026, according to the company’s announcement.

What kind of company is OKYO (OKYO)?

OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases. Its ordinary shares trade on the Nasdaq Capital Market under the ticker OKYO.

What clinical trial is OKYO (OKYO) planning for urcosimod?

OKYO plans a global Phase 3 pivotal clinical trial of urcosimod for neuropathic corneal pain in the second half of this year. The study is expected to enroll approximately 111 patients using a single-dose regimen.

On which exchange are OKYO (OKYO) shares listed?

OKYO Pharma’s ordinary shares are listed on the Nasdaq Capital Market under the ticker OKYO. The CEO’s recent purchase of 15,000 shares at $1.54 per share was executed on Nasdaq.

How many patients will the planned OKYO (OKYO) Phase 3 trial enroll?

The planned global Phase 3 pivotal trial of urcosimod for neuropathic corneal pain will enroll approximately 111 patients. The study will evaluate a single-dose regimen and is scheduled to start in the second half of this year.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

July 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On July 23, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing that OKYO Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on NASDAQ at $1.54 per share.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: July 23, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated July 23, 2026

4

Exhibit 99.1

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

London and New York, NY, July 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on NASDAQ at $1.54 per share.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 6.3 KB
• EX-99 GRAPHIC 4.4 KB